In vitro effects of histone deacetylase inhibitors and mitomycin C on tenon capsule fibroblasts and conjunctival melanoma cells

Archives of Ophthalmology

Volumn 127, Issue 4, 2009, Pages 414-420

  Cunneen, Thomas S ^a   Conway, R Max ^a   Madigan, Michele C ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; MITOMYCIN C; TRICHOSTATIN A;

APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; CELL GROWTH; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONJUNCTIVA TUMOR; CONTROLLED STUDY; DRUG MECHANISM; FIBROBLAST; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA CELL; PRIORITY JOURNAL;

APOPTOSIS; BUTYRATES; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CONJUNCTIVAL NEOPLASMS; CONNECTIVE TISSUE CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FIBROBLASTS; FLOW CYTOMETRY; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MELANOMA; MITOMYCIN; TETRAZOLIUM SALTS; THIAZOLES; TUMOR CELLS, CULTURED;

EID: 65249110495     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2009.64     Document Type: Article

References (41)

1. Anastassiou G, Heiligenhaus A, Bechrakis N, Bader E, Bornfeld N, Steuhl KP. Prognostic value of clinical and histopathological parameters in conjunctival melanomas: a retrospective study. Br J Ophthalmol. 2002;86(2):163-167.
2. Shields CL, Shields JA, Gunduz K, et al. Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150consecutive patients. Arch Ophthalmol. 2000;118(11):1497-1507.
3. Shields JA, Shields CL, De Potter P. Surgical management of circumscribed conjunctival melanomas. OphthalPlastReconstrSurg. 1998;14(3):208-215.
4. Missotten GS, KeijserS, De Keizer RJ, De Wolff-Rouendaal D. Conjunctival melanoma in the Netherlands: a nationwide study. Invest Ophthalmol Vis Sci. 2005; 46(1):75-82.
5. De Potter P, Shields CL, Shields JA, Menduke H. Clinical predictive factors for development of recurrence and metastasis in conjunctival melanoma: a review of 68 cases. Br J Ophthalmol. 1993;77(10):624-630.
6. Lommatzsch PK, Lommatzsch RE, Kirsch I, Fuhrmann P. Therapeutic outcome of patients suffering from malignant melanomas of the conjunctiva. Br J Ophthalmol. 1990;74(10):615-619.
7. Chalasani R, Giblin M, Conway RM. Role of topical chemotherapy for primary acquired melanosis and malignant melanoma of the conjunctiva and cornea: review of the evidence and recommendations for treatment. Clin Experiment Ophthalmol. 2006;34(7):708-714.
8. Finger PT, Sedeek RW, Chin KJ. Topical interferon alfa in the treatment of conjunctival melanoma and primary acquired melanosis complex. Am J Ophthalmol. 2008;145(1):124-129.
9. Fujioka M, Sakamoto M, Azumi A, Kanomata N. A case of conjunctival malignant melanoma treated with subconjunctival injection of interferon beta: efficacy and side effects. Nippon Ganka GakkaiZasshi. 2006;110(1):51-57.
10. Rootman J, Kumi C, Bussanich N, Damji K, Gudauskas G. Effect of subconjunc-tivally administered antineoplastics on experimentally induced intraocular malignant tumour. Can J Ophthalmol. 1989;24(6):254-258.
11. MonneretC. Histone deacetylase inhibitors. EurJMedChem. 2005;40(1):1-13.
12. Marks P, Rifkind RA, Richon VM, BreslowR, MillerT, Kelly WK. Histone deacety-lases and cancer: causes and therapies. Nat Rev Cancer. 2001;1(3):194-202.
13. Münster P, Marchion D, Bicaku E, et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol. 2007;25 (15):1979-1985.
14. Boyle GM, Martyn AC, Parsons PG. Histone deacetylase inhibitors and malignant melanoma. Pigment Cell Res. 2005;18(3):160-166.
15. LillehammerT, Engesaeter BO, Prasmickaite L, Maelandsmo GM, Fodstad O, En-gebraaten O. Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines. J Gene Med. 2007;9(6):440-451.
16. Paris M, Porcelloni M, Binaschi M, Fattori D. Histone deacetylase inhibitors: from bench to clinic. J Med Chem. 2008;51(6):1505-1529.
17. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007;12(10):1247-1252.
18. Kuwajima A, Iwashita J, Murata J, Abe T. The histone deacetylase inhibitor butyrate inhibits melanoma cell invasion of Matrigel. Anticancer Res. 2007;27(6B): 4163-4169.
19. Coradini D, Biffi A, Costa A, Pellizzaro C, Pirronello E, Di Fronzo G. Effect of sodium butyrate on human breast cancer cell lines. Cell Prolif. 1997;30(3-4): 149-159.
20. Newmark HL, Young CW. Butyrate and phenylacetate as differentiating agents: practical problems and opportunities. JCellBiochem Suppl. 1995;22:247-253.
21. Prasad KN, Sakamoto A. Effect of sodium butyrate in combination with prostaglandin E1 and inhibitors of cyclic nucleotide phosphodiesterase on human amela-notic melanoma cells in culture. Experientia. 1978;34(12):1575- 1576.
22. Rahmani M, Dai Y, Grant S. The histone deacetylase inhibitor sodium butyrate interacts synergistically with phorbol myristate acetate (PMA) to induce mitochondrial damage and apoptosis in human myeloid leukemia cells through a tumor necrosis factor-alpha-mediated process. Exp Cell Res. 2002;277(1):31-47.
23. Miller AA, Kurschel E, Osieka R, Schmidt CG. Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur J Cancer Clin Oncol. 1987;23 (9):1283-1287.
24. Tsuji N, Kobayashi M, Nagashima K, Wakisaka Y, Koizumi K. A new antifungal antibiotic, trichostatin. JAntibiot(Tokyo). 1976;29(1):1-6.
25. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. JBiolChem. 1990;265(28):17174-17179.
26. Saunders N, Dicker A, Popa C, Jones S, Dahler A. Histone deacetylase inhibitors as potential anti-skin cancer agents. Cancer Res. 1999;59(2):399-404.
27. Kortenhorst MS, Carducci MA, Shabbeer S. Acetylation and histone deacetylase inhibitors in cancer. Cell Oncol. 2006;28(5-6):191-222.
28. ShankarS, Srivastava RK. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. AdvExp Med Biol. 2008;615:261-298.
29. Nareyeck G, Wuestemeyer H, von der Haar D, Anastassiou G. Establishment of two cell lines derived from conjunctival melanomas. Exp Eye Res. 2005;81 (3):361-362.
30. Ramaesh K, Billson FA, Madigan MC. Effect of bile acids on fibroblast proliferation and viability. Eye. 1998;12(pt4):717-722.
31. Conway RM, Madigan MC, Penfold PL, Billson FA. Induction of apoptosis by sodium butyrate in the human Y-79 retinoblastoma cell line. Oncol Res. 1995; 7(6):289-297.
32. Burgess A, Ruefli A, Beamish H, et al. Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene. 2004;23(40):6693-6701.
33. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007;26(37):5541-5552.
34. Flørenes VA, Skrede M, Jorgensen K, Nesland JM. Deacetylase inhibition in ma-lignantmelanomas: impacton cell cycle regulation and survival. Melanoma Res.2004;14(3):173-181.
35. Peltonen K, Kiviharju TM, Jarvinen PM, Ra R, Laiho M. Melanoma cell lines are susceptible to histone deacetylase inhibitor TSA provoked cell cycle arrest and apoptosis. Pigment Cell Res. 2005;18(3):196-202.
36. Klisovic DD, Katz SE, Effron D, et al. Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines. Invest Ophthalmol Vis Sci. 2003;44(6):2390-2398.
37. Bandyopadhyay D, Mishra A, Medrano EE. Overexpression of histone deacety-lase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway. Cancer Res. 2004;64(21):7706-7710.
38. Munshi A, Kurland JF, NishikawaT, et al. Histone deacetylase inhibitors radio-sensitize human melanoma cells by suppressing DNA repair activity. Clin Can-cerRes. 2005;11(13):4912-4922.
39. WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA. 2000;97(18):10014-10019.
40. 40.Sambucetti LC, Fischer DD, Zabludoff S, et al. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. JBiolChem. 1999; 274(49):34940-34947.
41. Friedmann I, Atmaca A, Chow KU, Jager E, Weidmann E. Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumorcells of patients with colon cancer. J Chemother. 2006;18(4):415-420.